Biotechnology News

OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201

SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Wellcome Leap (Leap), a U.S. nonprofit founded by the Wellcome Trust to accelerate breakthroughs in human health, today announced that John Young and...

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced...

– Successful treatment of 91 patients with consistent safety and efficacy results observed to date; interim data to be presented at ESMO Congress in October 2026 – – Written feedback from FDA...

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™, an...

Cytek Biosciences and Sysmex Europe have signed an agreement establishing a strategic collaboration to enhance clinical flow cytometry workflows.

Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept. 09, 2026 (GLOBE...

– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all...

CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and...